This company has been marked as potentially delisted and may not be actively trading. Flexion Therapeutics (FLXN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsSustainabilityTrendsBuy This Stock FLXN vs. MENS, MOR, GMTX, ZYME, CALT, SBTX, MBX, AVTE, BIOA, and NLTXShould you be buying Flexion Therapeutics stock or one of its competitors? The main competitors of Flexion Therapeutics include Jyong Biotech (MENS), MorphoSys (MOR), Gemini Therapeutics (GMTX), Zymeworks (ZYME), Calliditas Therapeutics AB (publ) (CALT), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), BioAge Labs (BIOA), and Neoleukin Therapeutics (NLTX). Flexion Therapeutics vs. Its Competitors Jyong Biotech MorphoSys Gemini Therapeutics Zymeworks Calliditas Therapeutics AB (publ) Silverback Therapeutics MBX Biosciences Aerovate Therapeutics BioAge Labs Neoleukin Therapeutics Flexion Therapeutics (NASDAQ:FLXN) and Jyong Biotech (NASDAQ:MENS) are both pharmaceutical preparations industry companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment. Is FLXN or MENS more profitable? Jyong Biotech has a net margin of 0.00% compared to Flexion Therapeutics' net margin of -100.32%. Company Net Margins Return on Equity Return on Assets Flexion Therapeutics-100.32% N/A -44.26% Jyong Biotech N/A N/A N/A Does the media prefer FLXN or MENS? In the previous week, Jyong Biotech had 8 more articles in the media than Flexion Therapeutics. MarketBeat recorded 8 mentions for Jyong Biotech and 0 mentions for Flexion Therapeutics. Jyong Biotech's average media sentiment score of 0.53 beat Flexion Therapeutics' score of 0.00 indicating that Jyong Biotech is being referred to more favorably in the news media. Company Overall Sentiment Flexion Therapeutics Neutral Jyong Biotech Positive Which has preferable valuation and earnings, FLXN or MENS? Jyong Biotech has lower revenue, but higher earnings than Flexion Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFlexion Therapeutics$85.55M15.09-$113.71M-$2.01-12.76Jyong BiotechN/AN/AN/AN/AN/A Do institutionals and insiders believe in FLXN or MENS? 90.0% of Flexion Therapeutics shares are held by institutional investors. 9.1% of Flexion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryJyong Biotech beats Flexion Therapeutics on 4 of the 7 factors compared between the two stocks. Get Flexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FLXN vs. The Competition Export to ExcelMetricFlexion TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.29B$873.86M$5.76B$10.51BDividend YieldN/A4.84%5.53%4.57%P/E Ratio-12.761.1976.4326.62Price / Sales15.09114.73473.3192.90Price / CashN/A17.6437.4661.85Price / Book-75.466.4613.616.45Net Income-$113.71M-$5.56M$3.29B$271.57M Flexion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FLXNFlexion TherapeuticsN/A$25.66-0.1%N/AN/A$1.29B$85.55M-12.76257MENSJyong BiotechN/A$55.00+1.1%N/AN/A$4.18BN/A0.0031Gap DownMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$60.34+0.7%N/A+27.8%$2.61BN/A-60.3430ZYMEZymeworks2.3581 of 5 stars$16.46+3.9%$21.43+30.2%+28.2%$1.24B$122.87M-11.00460Positive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180SBTXSilverback TherapeuticsN/A$9.41-5.5%N/A-33.7%$339.31MN/A-3.8983High Trading VolumeMBXMBX Biosciences2.8873 of 5 stars$10.08+3.4%$37.63+273.3%-14.9%$337.12MN/A-2.2136Trending NewsAnalyst ForecastAVTEAerovate TherapeuticsN/A$7.07-8.2%N/A-88.0%$204.92MN/A-2.3620News CoveragePositive NewsHigh Trading VolumeBIOABioAge LabsN/A$4.93+0.6%N/AN/A$176.74MN/A0.00N/ANLTXNeoleukin TherapeuticsN/A$17.44-0.1%N/A-58.3%$163.90MN/A-5.6190High Trading Volume Related Companies and Tools Related Companies MENS Alternatives MOR Alternatives GMTX Alternatives ZYME Alternatives CALT Alternatives SBTX Alternatives MBX Alternatives AVTE Alternatives BIOA Alternatives NLTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FLXN) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Flexion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Flexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FLXN Stock Alerts